NISCAIR Online Periodicals Repository

NISCAIR ONLINE PERIODICALS REPOSITORY (NOPR)  >
NISCAIR PUBLICATIONS >
Research Journals >
Indian Journal of Biochemistry and Biophysics (IJBB) >
IJBB Vol.46 [2009] >
IJBB Vol.46(1) [February 2009] >


Title: Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease
Authors: Selvam, R
Maheswari, P
Kavitha, P
Ravichandran, M
Sas, Benedikt
Ramchand, C N
Keywords: Inflammatory bowel disease
Bacillus subtilis PB6
TNBS-induced colitis
Wistar rats
Cytokines
Issue Date: Feb-2009
Publisher: CSIR
Abstract: The pathophysiology of inflammatory bowel disease (IBD) involves the production of diverse lipid mediators, namely eicosanoid, lysophospholipids, and platelet-activating factor, in which phospholipase A₂ (PLA₂) is the key enzyme. Thus, it has been postulated that control of lipid mediators production by inhibition of PLA₂ would be useful for the treatment of IBD. This hypothesis has been tested in the present study by examining the therapeutic effect of a novel natural probitic Bacillus subtilis PB6 (ATCC- PTA 6737). B. subtilis PB6 is found to secrete surfactins (cyclic lipopeptides) which have anti-bacterial potential. These surfactins inhibit PLA₂, a rate-limiting enzyme involved in the arachidonic acid associated inflammatory pathway and could downregulate the inflammatory response by regulating the eicosanoid and cytokine pathways. With this concept, an experimental animal trial has been conducted in a rat model of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. The oral administration of PB6 suppresses the colitis as measured by mortality rate, changes in the weight gain, colon morphology and the levels of plasma cytokines. The animals treated orally with PB6 at 1.5 × 10⁸ CFU/kg thrice daily from day 4 to 10 significantly improve gross pathology of the colon and regain the colon weight to normal (p< 0.05), compared to TNBS-induced positive control. The plasma levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 and IFN-γ) are also significantly lowered (p<0.05) and anti-inflammatory cytokine (IL-10 and TGF-β) significantly (p<0.05) increased after the oral administration of PB6 on day 11. The present study supports the concept that PB6 inhibits PLA₂ by the secreting surfactins. In a clinical investigation, it is found to be well tolerated by all the healthy volunteers.
Page(s): 79-85
ISSN: 0301-1208
Source:IJBB Vol.46(1) [February 2009]

Files in This Item:

File Description SizeFormat
IJBB 46(1) 79-85.pdf330.34 kBAdobe PDFView/Open
 Current Page Visits: 773 
Recommend this item

 

National Knowledge Resources Consortium |  NISCAIR Website |  Contact us |  Feedback

Disclaimer: NISCAIR assumes no responsibility for the statements and opinions advanced by contributors. The editorial staff in its work of examining papers received for publication is helped, in an honorary capacity, by many distinguished engineers and scientists.

CC License Except where otherwise noted, the Articles on this site are licensed under Creative Commons License: CC Attribution-Noncommercial-No Derivative Works 2.5 India

Copyright © 2012 The Council of Scientific and Industrial Research, New Delhi. All rights reserved.

Powered by DSpace Copyright © 2002-2007 MIT and Hewlett-Packard | Compliant to OAI-PMH V 2.0

Home Page Total Visits: 592925 since 06-Feb-2009  Last updated on 18-Sep-2014Webmaster: nopr@niscair.res.in